Equities

Consun Pharmaceutical Group Ltd

Consun Pharmaceutical Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)6.08
  • Today's Change0.10 / 1.67%
  • Shares traded1.72m
  • 1 Year change+15.37%
  • Beta0.5973
Data delayed at least 15 minutes, as of May 03 2024 08:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Consun Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The pharmaceutical products of the Company include kidney medicines, contrast medium and others. The Company’s subsidiaries include Brilliant Reach Group Limited, Century International Develop Limited and Grand Reach Company Limited. Through its subsidiaries, the Company is also engaged in the research and development of pharmaceutical products.

  • Revenue in HKD (TTM)2.79bn
  • Net income in HKD846.58m
  • Incorporated2010
  • Employees3.13k
  • Location
    Consun Pharmaceutical Group Ltd71 Dongpeng Avenue, East SectionEconomic and Technological DevelopmentGuangzhou Luogang DistrictGUANGZHOU 510760ChinaCHN
  • Phone+86 2 082016888
  • Fax+86 2 082017468
  • Websitehttp://www.chinaconsun.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
China Isotope & Radiation Corp7.16bn400.31m3.51bn3.11k8.760.69223.140.48971.251.2522.3815.830.53124.221.792,305,873.006.216.5712.8213.2652.4859.8911.7012.621.73--0.19196.887.8215.35-5.432.88--2.92
Biocytogen Pharmaceuticals Beijng Co Ltd773.61m-413.24m3.51bn1.07k--4.14--4.53-1.04-1.041.942.120.273216.215.74725,713.60-14.59---18.88--70.59---53.42--1.24-21.300.4077--34.28--36.38------
CARsgen Therapeutics Holdings Ltd0.00-806.94m3.56bn516.00--1.83-----1.45-1.450.003.380.00----0.00-29.79---32.14----------9.54--0.0452------16.19------
CK Life Sciences Intl (Holdings) Inc5.32bn17.25m3.94bn1.93k229.050.940634.760.74030.00180.00180.55380.43590.47282.964.742,755,038.000.15321.110.2111.4330.7630.520.32412.420.85120.87960.586159.000.89360.3407-86.93-42.010.2784--
Jiangsu Recbio Technology Co Ltd0.00-617.19m4.44bn472.00--3.81-----1.28-1.280.002.410.00----0.00-25.47---30.68----------2.33--0.378------20.86------
Consun Pharmaceutical Group Ltd2.79bn846.58m4.94bn3.13k5.741.265.291.771.061.063.504.830.49812.089.10893,815.3015.1312.0422.5719.2574.1974.5530.3724.892.62--0.115541.5310.717.0314.8811.01--18.43
Ocumension Therapeutics265.85m-409.82m4.97bn444.00--1.57--18.71-0.6316-0.63160.40954.560.0783.612.12598,764.60-12.03-38.78-13.21-41.4758.6062.30-154.16-975.823.72--0.0451--54.99--5.68--319.66--
Alphamab Oncology236.08m-227.25m5.01bn435.00--2.78--21.21-0.2363-0.23630.24591.870.10280.770519.34542,704.00-9.90-18.72-11.69-21.9474.75---96.26-415.555.55--0.1333--31.12--35.35---13.12--
Microport NeuroTech Ltd-100.00bn-100.00bn5.20bn571.00------------------------------------------------21.61--768.73------
Shandong Boan Biotechnology Co Ltd667.02m-128.82m5.22bn813.00--3.66--7.82-0.2529-0.25291.312.800.27321.352.53820,436.90-5.28---7.02--66.16---19.31--0.8383-7.470.2491--19.80--64.02------
ImmuneOnco Biopharmaceuticls Shanghi Inc-100.00bn-100.00bn5.26bn---------------------------------------------------28.25--5.82------
Ascentage Pharma Group International239.54m-998.84m5.34bn583.00--81.90--22.29-3.53-3.530.84850.22470.08332.382.22410,875.00-34.73-44.93-52.82-57.0486.2487.68-417.02-976.101.42-15.030.9622--5.85100.76-4.84--2.82--
Beijing Luzhu Biotechnology Co Ltd0.00-269.07m5.47bn133.00--4.96-----1.34-1.340.005.44------0.00----------------6.41--0.0185------65.62------
Qyuns Therapeutics Co Ltd0.00-513.13m5.69bn323.00--13.28-----2.31-2.310.001.93---------------------------64.020.4436------27.45------
Sihuan Pharmaceutical Holdings Group Ltd2.01bn-58.29m5.69bn2.87k--1.19--2.83-0.0063-0.00630.2160.51260.15720.81014.72699,054.30-2.18-6.85-3.34-9.1069.6475.81-13.85-36.231.35-2.630.1863---14.70-8.6097.23--0.9325--
New Horizon Health Ltd1.47bn119.37m6.47bn1.04k59.202.0141.644.400.23890.23893.227.040.45362.162.081,673,916.003.67--3.99--88.74--8.10--10.50--0.1305--259.54--97.40------
Data as of May 03 2024. Currency figures normalised to Consun Pharmaceutical Group Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

6.95%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 05 Apr 202421.16m2.61%
Fidelity Management & Research Co. LLCas of 29 Feb 202410.46m1.29%
Dimensional Fund Advisors LPas of 28 Mar 20249.11m1.12%
Norges Bank Investment Managementas of 31 Dec 20234.24m0.52%
AllianceBernstein Ltd.as of 31 Dec 20233.33m0.41%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 20232.49m0.31%
Lacuna Verm�gen GmbHas of 30 Jun 20212.44m0.30%
Schroder Investment Management North America, Inc.as of 28 Feb 20211.26m0.16%
Fidelity Investments Canada ULCas of 29 Feb 20241.01m0.12%
Thrivent Asset Management LLCas of 31 Jan 2024912.00k0.11%
More ▼
Data from 30 Jun 2021 - 24 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.